☰

Giredestrant (GDC-9545) Clinical Trials (November 2026): The Oral SERD Under FDA Priority Review — First With Positive Curative-Setting Phase 3 (lidERA) in ER-Positive, HER2-Negative Breast Cancer

Last updated: November 5, 2026

Drug profile:

Giredestrant (GDC-9545, RG6171) is an investigational next-generation oral selective estrogen receptor degrader (SERD) from Roche / Genentech, for estrogen-receptor-positive (ER-positive), HER2-negative breast cancer. It is a once-daily pill. As of November 2026 it is not yet FDA-approved — it is under FDA review (see below).

Mechanism of action:

Giredestrant both blocks and degrades the estrogen receptor, shutting off the estrogen signaling that drives ER-positive breast cancer. Crucially, it stays active against ESR1-mutant tumors — the mutations that make cancers resistant to aromatase inhibitors — and, unlike fulvestrant (an injectable SERD), it is taken orally.

Regulatory status:

Under FDA Priority Review for adjuvant early-stage (stage I–III) ER-positive, HER2-negative breast cancer (based on the Phase 3 lidERA trial) — FDA decision expected ~November 30, 2026. A second NDA, for giredestrant + everolimus in ESR1-mutated advanced disease (Phase 3 evERA), is also under review, decision expected ~December 2026. It is the first and only oral SERD with positive Phase 3 results in the curative (early-stage) setting.

Why Giredestrant Matters — In Plain Language

Most breast cancer is ER-positive — it grows on estrogen. The standard way to treat it is endocrine (hormone) therapy: aromatase inhibitors (which lower estrogen) and fulvestrant (which degrades the estrogen receptor but must be given as a monthly injection into the muscle). Over time, many cancers develop ESR1 mutations that let them keep growing despite aromatase inhibitors — the point where endocrine therapy starts to fail.

What an oral SERD changes. Giredestrant is a pill that degrades the estrogen receptor and still works against ESR1-mutant tumors. That combines the mechanism of fulvestrant with the convenience of a daily tablet — and adds activity where standard endocrine therapy runs out of road.

The milestone. Several oral SERDs are in development, but they have all been tested in advanced/metastatic disease. Giredestrant is the first to succeed in the curative, early-stage setting: in the Phase 3 lidERA trial, adding adjuvant giredestrant reduced the risk of the cancer coming back (invasive disease recurrence) or death by about 30% versus standard adjuvant endocrine therapy. That result is the basis of the FDA Priority Review now underway, with a decision expected around November 30, 2026.

Under FDA Review — Two Pending Decisions

Giredestrant is not FDA-approved yet. Two New Drug Applications are under FDA review as of November 2026, each backed by a positive Phase 3 trial. Trial identifiers and settings below are verified against ClinicalTrials.gov; the regulatory dates are from Roche/Genentech announcements.

⏳ Priority Review — Adjuvant Early-Stage ER+/HER2- Breast Cancer (lidERA)

Pivotal trial: lidERA Phase 3 (NCT04961996, n≈4,170) · Setting: adjuvant treatment of ER-positive, HER2-negative stage I–III early breast cancer · Result: reduced the risk of invasive disease recurrence or death by ~30% vs standard adjuvant endocrine therapy · FDA: Priority Review, decision expected ~November 30, 2026 · Significance: the first and only oral SERD positive in the curative setting. (Trial no longer recruiting.)

⏳ Under Review — Giredestrant + Everolimus, ESR1-Mutated Advanced Disease (evERA)

Pivotal trial: evERA Phase 3 (NCT05306340, n≈373) · Setting: giredestrant + everolimus vs physician's-choice endocrine therapy + everolimus in ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer · FDA: New Drug Application accepted, decision expected ~December 2026. (Trial no longer recruiting.)

★ First Oral SERD Into the Curative Setting

Oral ER-targeted agents so far have all been advanced-disease drugs — elacestrant (Orserdu), imlunestrant (Inluriyo), vepdegestrant (Veppanu), and camizestrant (Etcamah) are FDA-approved only in ESR1-mutated advanced/metastatic breast cancer. Giredestrant's lidERA result moves the class into early, potentially curable breast cancer for the first time, where the goal is preventing recurrence rather than controlling metastatic disease. If approved on the November 2026 decision, it would be the first oral SERD available in the adjuvant setting.

Giredestrant is investigational; it can only be received through a clinical trial or, if approved, by prescription after that date. Nothing here is a guarantee of approval.

Key Registrational Phase 3 Trials

The trials behind giredestrant's filings and program. lidERA and evERA (above) support the two NDAs; the trials below round out the Phase 3 program. NCTs, phases, settings, and enrollment are verified against ClinicalTrials.gov (November 2026).

Recruiting Giredestrant Trials (Open Now)

Giredestrant trials actively recruiting as of November 2026 (ClinicalTrials.gov-verified), plus one not yet recruiting. These are the ones a patient could potentially enroll in today.

The Broader Oral SERD / Next-Generation Endocrine Landscape

Giredestrant is one of several next-generation endocrine agents racing to improve on aromatase inhibitors and injectable fulvestrant — especially in ESR1-mutant, endocrine-resistant disease. The class includes FDA-approved agents for ESR1-mutated advanced disease — the oral SERDs elacestrant (Orserdu), imlunestrant (Inluriyo, Sep 2025; with abemaciclib Sep 2026), and camizestrant (Etcamah, accelerated approval Sep 2026 with a CDK4/6 inhibitor on emergent ESR1 mutation), and the PROTAC estrogen-receptor degrader vepdegestrant (Veppanu, ARV-471, May 2026). Giredestrant's distinguishing move is being first into the early-stage/adjuvant (curative) setting via lidERA. If your tumor is ER-positive, HER2-negative — particularly if it carries an ESR1 mutation after prior endocrine therapy — trials of these agents may be options.

Expected Side Effects

Giredestrant is generally well tolerated as an oral endocrine therapy. Reported effects include fatigue, arthralgia (joint pain), and an asymptomatic slowing of the heart rate (sinus bradycardia) that has been observed in trials and is monitored during treatment. As with other endocrine agents, hot flashes and mild gastrointestinal effects can occur. The overall side-effect profile also depends on what giredestrant is combined with — for example a CDK4/6 inhibitor (which adds low blood counts and, for abemaciclib, diarrhea) or everolimus (which adds mouth sores and metabolic effects). This is general information, not a complete list — your oncologist can explain what to expect for a specific regimen.

Frequently Asked Questions

What is giredestrant (GDC-9545) and how does it work?

Giredestrant (GDC-9545, RG6171) is an investigational next-generation oral selective estrogen receptor degrader (SERD) from Roche/Genentech. It is a once-daily pill that both blocks and degrades the estrogen receptor, shutting down the estrogen signaling that drives ER-positive breast cancer. Unlike aromatase inhibitors it stays active against ESR1-mutant tumors, and unlike fulvestrant (an injectable SERD) it is taken orally.

Is giredestrant FDA-approved?

Not yet. As of November 2026 giredestrant is investigational and under FDA review on two fronts: Priority Review for adjuvant early-stage ER-positive, HER2-negative breast cancer (Phase 3 lidERA), decision expected ~November 30, 2026; and a second application for giredestrant + everolimus in ESR1-mutated advanced disease (Phase 3 evERA), decision expected ~December 2026.

Why is giredestrant considered a first-in-class milestone?

It is the first and only oral SERD with positive Phase 3 results in the curative (early-stage/adjuvant) setting. In lidERA, adjuvant giredestrant reduced the risk of invasive disease recurrence or death by about 30% vs standard adjuvant endocrine therapy. Every other approved or filed oral SERD (such as elacestrant) has positive data only in advanced/metastatic disease.

Who might be eligible for a giredestrant trial?

Giredestrant trials are for ER-positive, HER2-negative breast cancer across early-stage and advanced settings; some target ESR1-mutant, endocrine-resistant disease. Recruiting trials as of November 2026 include a neoadjuvant trial of abemaciclib + giredestrant, the kalitERA Phase 3b study of giredestrant in early breast cancer, and the MoonROSE Phase 1b/2 trial (GDC-4198 + giredestrant) after a CDK4/6 inhibitor in advanced disease; the pionERA Phase 3 (giredestrant vs fulvestrant) is now closed to new enrollment. Eligibility depends on ER/HER2 status, prior treatment, and stage — use the free ClinTrialFinder matcher to check.

What are the side effects of giredestrant?

Generally well tolerated: fatigue, arthralgia (joint pain), and an asymptomatic slowing of the heart rate (sinus bradycardia) monitored in trials; hot flashes and mild GI effects can occur. The profile also depends on the combination partner (a CDK4/6 inhibitor or everolimus).

Find giredestrant / ER-positive breast cancer trials matched to your situation

Choose your diagnosis for trial matching